Aperio Group’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $14.9M | Buy |
125,215
+184
| +0.1% | +$22.4K | 0.04% | 414 |
|
|
2020
Q3 | $14.3M | Sell |
125,031
-2,718
| -2% | -$321K | 0.05% | 362 |
|
|
2020
Q2 | $14.6M | Sell |
127,749
-42,874
| -25% | -$4.55M | 0.05% | 343 |
|
|
2020
Q1 | $13.7M | Buy |
170,623
+32,547
| +24% | +$3.37M | 0.06% | 313 |
|
|
2019
Q4 | $14.7M | Buy |
138,076
+4,041
| +3% | +$421K | 0.05% | 391 |
|
|
2019
Q3 | $14.3M | Buy |
134,035
+13,182
| +11% | +$1.35M | 0.06% | 367 |
|
|
2019
Q2 | $12.3M | Buy |
120,853
+12,752
| +12% | +$1.23M | 0.05% | 409 |
|
|
2019
Q1 | $9.72M | Buy |
108,101
+29,027
| +37% | +$2.52M | 0.04% | 471 |
|
|
2018
Q4 | $6.58M | Sell |
79,074
-7,646
| -9% | -$717K | 0.03% | 537 |
|
|
2018
Q3 | $9.36M | Sell |
86,720
-6,407
| -7% | -$703K | 0.04% | 458 |
|
|
2018
Q2 | $10.2M | Buy |
93,127
+1,914
| +2% | +$199K | 0.05% | 428 |
|
|
2018
Q1 | $9.15M | Sell |
91,213
-4,088
| -4% | -$419K | 0.05% | 447 |
|
|
2017
Q4 | $9.39M | Sell |
95,301
-9,975
| -9% | -$946K | 0.05% | 434 |
|
|
2017
Q3 | $9.86M | Buy |
105,276
+995
| +1% | +$106K | 0.06% | 396 |
|
|
2017
Q2 | $11.6M | Buy |
104,281
+7,231
| +7% | +$765K | 0.07% | 329 |
|
|
2017
Q1 | $9.53M | Buy |
97,050
+9,507
| +11% | +$906K | 0.07% | 352 |
|
|
2016
Q4 | $8.04M | Sell |
87,543
-3,529
| -4% | -$304K | 0.06% | 365 |
|
|
2016
Q3 | $7.71M | Buy |
91,072
+8,089
| +10% | +$679K | 0.06% | 397 |
|
|
2016
Q2 | $6.76M | Buy |
82,983
+13,793
| +20% | +$1.05M | 0.05% | 410 |
|
|
2016
Q1 | $4.94M | Buy |
69,190
+23,929
| +53% | +$1.6M | 0.04% | 483 |
|
|
2015
Q4 | $3.22M | Buy |
45,261
+7,211
| +19% | +$485K | 0.03% | 587 |
|
|
2015
Q3 | $2.34M | Buy |
38,050
+1,770
| +5% | +$124K | 0.02% | 682 |
|
|
2015
Q2 | $2.63M | Buy |
36,280
+2,972
| +9% | +$219K | 0.03% | 617 |
|
|
2015
Q1 | $2.56M | Buy |
33,308
+2,683
| +9% | +$192K | 0.03% | 598 |
|
|
2014
Q4 | $2.05M | Buy |
30,625
+965
| +3% | +$60.9K | 0.03% | 634 |
|
|
2014
Q3 | $1.8M | Buy |
29,660
+1,763
| +6% | +$109K | 0.02% | 638 |
|
|
2014
Q2 | $1.64M | Buy |
27,897
+3,124
| +13% | +$183K | 0.02% | 651 |
|
|
2014
Q1 | $1.44M | Buy |
+24,773
| New | +$1.33M | 0.02% | 828 |
|
|
2013
Q4 | – | Sell |
-20,798
| Closed | -$1.23M | – | 822 |
|
|
2013
Q3 | $1.28M | Buy |
20,798
+4,638
| +29% | +$278K | 0.02% | 759 |
|
|
2013
Q2 | $980K | Buy |
+16,160
| New | +$963K | 0.02% | 766 |
|
Other funds holding DGX
FMI
DSA
Aperio Group's DGX Position: Q4 2020 in Review
Aperio Group increased its Quest Diagnostics (DGX) stake by 0.15% in Q4 2020, buying an estimated $22.4K and bringing the position to 125,215 shares worth $14.9M. The position accounts for 0.04% of the portfolio, ranked #414.
Aperio Group first reported a position in DGX in Q2 2013 and has held it in 30 quarters since. 812 funds tracked by Wall St. Rank hold DGX as of Q4 2020.
- Aperio Group held 125,215 shares of Quest Diagnostics worth $14.9M as of Q4 2020.
- Aperio Group bought 184 Quest Diagnostics shares in Q4 2020, an estimated $22.4K.
- Quest Diagnostics made up 0.04% of Aperio Group's portfolio in Q4 2020, its #414 holding.
- Aperio Group first reported a position in Quest Diagnostics in Q2 2013 and has held it in 30 quarters since.
- 812 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.